{
  "ticker": "AXE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968859",
  "id": "02968859",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0827",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrq1tt9h7cqw.pdf",
  "summary": "### **Archer Materials \u2013 Quarterly Report (Appendix 4C) \u2013 Key Takeaways**  \n\n- **Cash Position**: Closing cash balance of **$13.7M** (no debt).  \n- **R&D Progress**:  \n  - **Quantum Computing (12CQ)**: Extended collaboration with Queen Mary University London to advance qubit development (targeting 1HCY26 demonstration).  \n  - **Biochip**:  \n    - Signed agreement with **Paragraf** to improve graphene-based biosensor (gFET) for blood potassium testing.  \n    - Fabricated integrated silicon chip (gFET + readout circuitry) for handheld blood-testing device.  \n- **Strategic Move**: Formed **advisory committee** (chaired by semiconductor/medtech experts) to guide commercialization.  \n- **Investments**: Holdings in **Volatus Capital (CSE:VC)** and **ChemX Materials (ASX:CMX)**.  \n- **Burn Rate**: Net operating cash outflow of **$1.78M** (7.7 quarters of runway at current rate).  \n\n**No material capital-raising or trading halt information identified.**",
  "usage": {
    "prompt_tokens": 5162,
    "completion_tokens": 236,
    "total_tokens": 5398,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T22:34:57.023898"
}